Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.
Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.
After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.
Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.
Fresenius Kabi launches Levothyroxine Sodium Injection in the U.S. It is the first, and only, pre-mixed solution of this medication currently available in the U.S.
Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.
Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.
Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.
Glycopyrrolate is now available in the company’s Simplist™ ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio. It is the first FDA-approved manufacturer-supplied ready-to-administer prefilled syringe for this medication in the U.S.
Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.